Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of November 2024, specifically dated November 8, 2024. The report serves to disseminate a press release regarding a significant regulatory milestone for the Company's ProSense Cryoablation technology in the treatment of early-stage low-risk breast cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes
The primary material event reported is the favorable vote by an FDA Advisory Panel regarding the benefit-risk profile of Icecure's ProSense Cryoablation system for early-stage low-risk breast cancer. This event is incorporated by reference into the Company's existing Registration Statements on Form F-3 and Form S-8.
Guidance, Outlook, and Risks
The filing incorporates the "Forward Looking Statements" section from the attached press release (Exhibit 99.1) by reference. While the specific text of these statements is not included in the provided content, the filing indicates that the Company is proceeding with regulatory expectations based on the Advisory Panel's vote. No specific financial guidance or new risk factors are detailed in the body of this Form 6-K.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the specific details of the FDA Advisory Panel vote and the "Forward Looking Statements."
- Confirm the status of the Company's Registration Statements (Form F-3 and Form S-8) to see how this event impacts future capital raising or employee stock plans.
- Review subsequent filings for any official FDA decision following the Advisory Panel's recommendation.
- Check the Company's most recent 20-F or 10-Q for actual financial performance data, as this filing contains none.